Intravitreal Aflibercept Injection as a Surgical Adjuvant in Severe Proliferative Diabetic Retinopathy

NCT01805297 Phase 2 COMPLETED Results posted

To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.

Details

Lead sponsor	University of Oklahoma
Phase	Phase 2
Status	COMPLETED
Enrolment	12
Start date	2013-03
Completion	2015-11

Conditions

• Vitreous Hemorrhage

Interventions

• Intravitreal Aflibercept Injection
• Standard Vitrectomy

Primary outcomes

• Rate of Resolved Post-operative Vitreous Hemorrhage. — 24 weeks
  Percentage of patients who had no vitreous hemorrhage before or at week 24

Countries

United States